CN114377125A - MAdCAM拮抗剂的剂量方案 - Google Patents

MAdCAM拮抗剂的剂量方案 Download PDF

Info

Publication number
CN114377125A
CN114377125A CN202111331776.8A CN202111331776A CN114377125A CN 114377125 A CN114377125 A CN 114377125A CN 202111331776 A CN202111331776 A CN 202111331776A CN 114377125 A CN114377125 A CN 114377125A
Authority
CN
China
Prior art keywords
ser
val
thr
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111331776.8A
Other languages
English (en)
Chinese (zh)
Inventor
F·卡塔迪
R·A·克莱尔
G·M·科默
V·普拉丹
A·艾哈迈德
M·哈桑-扎阿伊
M·K·蒂利
W·张
A·班纳吉
K·M·佩奇
M·S·文森特
D·J·冯沙克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55275128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114377125(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN114377125A publication Critical patent/CN114377125A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
CN202111331776.8A 2015-01-09 2016-01-06 MAdCAM拮抗剂的剂量方案 Pending CN114377125A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562101877P 2015-01-09 2015-01-09
US62/101,877 2015-01-09
US201562263197P 2015-12-04 2015-12-04
US62/263,197 2015-12-04
US201562263910P 2015-12-07 2015-12-07
US62/263,910 2015-12-07
CN201680014443.3A CN107427576A (zh) 2015-01-09 2016-01-06 MAdCAM拮抗剂的剂量方案
PCT/IB2016/050047 WO2016110806A2 (en) 2015-01-09 2016-01-06 Dosage regimen for madcam antagonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680014443.3A Division CN107427576A (zh) 2015-01-09 2016-01-06 MAdCAM拮抗剂的剂量方案

Publications (1)

Publication Number Publication Date
CN114377125A true CN114377125A (zh) 2022-04-22

Family

ID=55275128

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111331776.8A Pending CN114377125A (zh) 2015-01-09 2016-01-06 MAdCAM拮抗剂的剂量方案
CN201680014443.3A Pending CN107427576A (zh) 2015-01-09 2016-01-06 MAdCAM拮抗剂的剂量方案
CN202111331779.1A Pending CN114732899A (zh) 2015-01-09 2016-01-06 MAdCAM拮抗剂的剂量方案

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201680014443.3A Pending CN107427576A (zh) 2015-01-09 2016-01-06 MAdCAM拮抗剂的剂量方案
CN202111331779.1A Pending CN114732899A (zh) 2015-01-09 2016-01-06 MAdCAM拮抗剂的剂量方案

Country Status (16)

Country Link
US (2) US10851163B2 (cg-RX-API-DMAC7.html)
EP (2) EP3242684B1 (cg-RX-API-DMAC7.html)
JP (2) JP6779621B2 (cg-RX-API-DMAC7.html)
KR (1) KR102756784B1 (cg-RX-API-DMAC7.html)
CN (3) CN114377125A (cg-RX-API-DMAC7.html)
AU (2) AU2016205852B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017014793A2 (cg-RX-API-DMAC7.html)
CA (1) CA2916283C (cg-RX-API-DMAC7.html)
CL (1) CL2017001756A1 (cg-RX-API-DMAC7.html)
EA (1) EA037288B1 (cg-RX-API-DMAC7.html)
ES (1) ES2927958T3 (cg-RX-API-DMAC7.html)
IL (1) IL253247B (cg-RX-API-DMAC7.html)
MA (1) MA41314A (cg-RX-API-DMAC7.html)
MX (1) MX385589B (cg-RX-API-DMAC7.html)
SG (1) SG11201705604WA (cg-RX-API-DMAC7.html)
WO (1) WO2016110806A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6904905B2 (ja) * 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
CA2916283C (en) * 2015-01-09 2024-07-02 Pfizer Inc. MADCAM ANTAGONIST DOSING REGIMEN
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102787394B1 (ko) 2017-07-14 2025-03-26 화이자 인크. MAdCAM에 대한 항체
CN108118093A (zh) * 2018-03-06 2018-06-05 谢琳 Linc00426在制备骨肉瘤转移诊断产品中的用途
US20210030868A1 (en) * 2019-07-29 2021-02-04 Cai Gu Huang Formulation of antibody based drugs for treating lung cancer by inhalation
CN114164211B (zh) * 2021-09-16 2024-02-27 中国人民解放军海军军医大学 lncRNA及其在肿瘤诊断、治疗和预后判断中的应用
CN113789328A (zh) * 2021-09-16 2021-12-14 中国人民解放军海军军医大学 lncRNA及其在免疫调控及免疫相关疾病诊治中的应用
CN116631510B (zh) * 2022-10-28 2024-01-12 中国人民解放军军事科学院军事医学研究院 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置
JP2025538586A (ja) * 2022-11-22 2025-11-28 武田薬品工業株式会社 非アルコール性脂肪性肝炎の治療のためのＭＡｄＣＡＭ－１抗体の投薬レジメン

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US20070202097A1 (en) * 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
DOP2005000002A (es) * 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
US20100119517A1 (en) 2005-07-08 2010-05-13 Pfizer Inc Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue
PE20070374A1 (es) 2005-07-08 2007-05-12 Pfizer Ltd ANTICUERPOS ANTI-MAdCAM
WO2007007160A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
WO2007007151A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
DE102010013830A1 (de) * 2010-03-26 2011-09-29 Carl Zeiss Microlmaging Gmbh Mikroskop und Verfahren zur mikroskopischen Erfassung von Licht einer Probe
JP6615745B2 (ja) * 2013-03-27 2019-12-04 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
CA2916283C (en) * 2015-01-09 2024-07-02 Pfizer Inc. MADCAM ANTAGONIST DOSING REGIMEN

Also Published As

Publication number Publication date
EP4112079A1 (en) 2023-01-04
JP2021011493A (ja) 2021-02-04
US10851163B2 (en) 2020-12-01
NZ733365A (en) 2024-05-31
US20210324070A1 (en) 2021-10-21
MX2017009047A (es) 2019-01-30
IL253247B (en) 2022-04-01
JP7142200B2 (ja) 2022-09-27
US11884726B2 (en) 2024-01-30
BR112017014793A2 (pt) 2018-01-09
KR102756784B1 (ko) 2025-01-16
JP6779621B2 (ja) 2020-11-04
JP2016128441A (ja) 2016-07-14
CN107427576A (zh) 2017-12-01
CA2916283C (en) 2024-07-02
EA037288B1 (ru) 2021-03-04
WO2016110806A2 (en) 2016-07-14
US20180273619A1 (en) 2018-09-27
ES2927958T3 (es) 2022-11-14
EP3242684A2 (en) 2017-11-15
EA201791227A1 (ru) 2017-12-29
MX385589B (es) 2025-03-12
IL253247A0 (en) 2017-08-31
MA41314A (fr) 2017-11-14
WO2016110806A3 (en) 2016-10-20
CN114732899A (zh) 2022-07-12
CL2017001756A1 (es) 2018-02-09
AU2016205852A1 (en) 2017-07-20
SG11201705604WA (en) 2017-08-30
AU2021250850B2 (en) 2023-06-01
AU2021250850A1 (en) 2021-11-04
NZ771184A (en) 2024-10-25
KR20170129104A (ko) 2017-11-24
AU2016205852B2 (en) 2021-09-16
EP3242684B1 (en) 2022-07-27
CA2916283A1 (en) 2016-07-09

Similar Documents

Publication Publication Date Title
JP7142200B2 (ja) ＭＡｄＣＡＭアンタゴニストの投与レジメン
US10689439B2 (en) Optimized anti-TL1A antibodies
CN111499747A (zh) 一种抗cd73单克隆抗体及其应用
US20120189618A1 (en) Superior efficacy of cd37 antibodies in cll blood samples
JP7706458B2 (ja) 腎疾患の治療に使用するための抗αｖβ８インテグリン抗体
JP2024042072A (ja) 抗ｃｔｌａ－４結合タンパク質およびその使用方法
TW202327650A (zh) 治療多發性骨髓瘤之方法
JP2023545075A (ja) ＣＤ１ａ抗体およびその使用
HK40073033A (en) Dosage regimen for madcam antagonists
HK40077412A (en) Dosage regimen for madcam antagonists
RU2853818C9 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
RU2853818C1 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
CA3048198A1 (en) Methods of treating multiple myeloma
US9211329B2 (en) Method of treating inflammatory bowel disease
RU2796586C2 (ru) Антитела к cd6 для лечения тяжелой астмы
WO2024187041A1 (en) Regulation of fat storage and metabolism in humans by engaging innate immunity via ap1/cd47 axis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073033

Country of ref document: HK